<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693342</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000597674</org_study_id>
    <secondary_id>GOG-OVM0703</secondary_id>
    <nct_id>NCT00693342</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission</brief_title>
  <official_title>A Randomized Phase III Trial in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer With a Polyvalent Vaccine-KLH Conjugate + OPT-821 Versus OPT-821</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from tumor antigens may help the body build an effective immune&#xD;
      response to kill tumor cells. Biological therapies, such as OPT-821, may stimulate the immune&#xD;
      system in different ways and stop tumor cells from growing. Giving vaccine therapy together&#xD;
      with OPT-821 may kill more tumor cells. It is not yet known whether giving vaccine therapy&#xD;
      together with OPT-821 is more effective than OPT-821 alone in treating ovarian epithelial&#xD;
      cancer, fallopian tube cancer, or primary peritoneal cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying vaccine therapy and OPT-821 to see how&#xD;
      well they work compared with OPT-821 alone in treating patients with ovarian epithelial&#xD;
      cancer, fallopian tube cancer, or primary peritoneal cancer in complete remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare the progression-free survival of patients with ovarian epithelial, fallopian&#xD;
           tube, or primary peritoneal cancer in second or third complete clinical remission&#xD;
           treated with a polyvalent antigen-KLH conjugate vaccine (GM2-KLH, Globo-H-KLH,&#xD;
           Tn-MUC1-32mer-KLH, TF-KLH, and sTn-KLH) in combination with OPT-821 vs OPT-821 alone.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare the incidence of toxicities in patients treated with these regimens.&#xD;
&#xD;
        -  To compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  To characterize the immune response (by ELISA) in a limited sampling of patients, in&#xD;
           order to determine if the outcome correlates with antigen-specific immune titers.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive polyvalent antigen-KLH conjugate vaccine in combination with&#xD;
           OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.&#xD;
&#xD;
        -  Arm II: Patients receive OPT-821 SC once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75,&#xD;
           and 87.&#xD;
&#xD;
      Patients undergo blood sample collection periodically for correlative studies. Samples are&#xD;
      analyzed for antibody expression to antigens (i.e., Tn-MUC1-32mer, GM2, Globo-H, TF, sTN, and&#xD;
      Tn) by ELISA. IgM and IgG titers are also measured.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years, every&#xD;
      6 months for 3 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Never opened to accrual, a GOG working number, not developed into a clinical trial.&#xD;
  </why_stopped>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicities</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of outcome with antigen-specific immune titers in a limited sampling of patients</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive polyvalent antigen-KLH conjugate vaccine in combination with OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive OPT-821 SC once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>immunological adjuvant OPT-821</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>polyvalent antigen-KLH conjugate vaccine</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal&#xD;
             cancer&#xD;
&#xD;
               -  Any stage or grade at diagnosis allowed&#xD;
&#xD;
          -  Has undergone initial cytoreductive surgery or received at least one platinum-based&#xD;
             chemotherapy regimen&#xD;
&#xD;
               -  Recurred on initial therapy, but is now in second or third complete clinical&#xD;
                  remission as defined by the following:&#xD;
&#xD;
                    -  Serum CA-125 normal&#xD;
&#xD;
                    -  Negative physical examination&#xD;
&#xD;
                    -  No definitive evidence of disease by CT scan of the abdomen and pelvis&#xD;
                       (lymph nodes and/or soft tissue abnormalities ≤ 1.0 cm are not considered&#xD;
                       definitive evidence of disease)&#xD;
&#xD;
                         -  A positive PET scan is allowed provided other criteria are met and MRI&#xD;
                            or CT scan are negative&#xD;
&#xD;
               -  Completed last course of chemotherapy within the past 4 months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  GOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 times ULN&#xD;
&#xD;
          -  SGOT ≤ 2.0 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.0 times ULN&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sabbatini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan S. Berek, MD</last_name>
    <affiliation>Stanford Comprehensive Cancer Center - Palo Alto</affiliation>
  </overall_official>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 6, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <keyword>stage IA primary peritoneal cavity cancer</keyword>
  <keyword>stage IB primary peritoneal cavity cancer</keyword>
  <keyword>stage IC primary peritoneal cavity cancer</keyword>
  <keyword>stage IIA primary peritoneal cavity cancer</keyword>
  <keyword>stage IIB primary peritoneal cavity cancer</keyword>
  <keyword>stage IIC primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIA primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIB primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIC primary peritoneal cavity cancer</keyword>
  <keyword>stage IV primary peritoneal cavity cancer</keyword>
  <keyword>stage IA fallopian tube cancer</keyword>
  <keyword>stage IB fallopian tube cancer</keyword>
  <keyword>stage IC fallopian tube cancer</keyword>
  <keyword>stage IIA fallopian tube cancer</keyword>
  <keyword>stage IIB fallopian tube cancer</keyword>
  <keyword>stage IIC fallopian tube cancer</keyword>
  <keyword>stage IIIA fallopian tube cancer</keyword>
  <keyword>stage IIIB fallopian tube cancer</keyword>
  <keyword>stage IIIC fallopian tube cancer</keyword>
  <keyword>stage IV fallopian tube cancer</keyword>
  <keyword>stage IA ovarian epithelial cancer</keyword>
  <keyword>stage IB ovarian epithelial cancer</keyword>
  <keyword>stage IC ovarian epithelial cancer</keyword>
  <keyword>stage IIA ovarian epithelial cancer</keyword>
  <keyword>stage IIB ovarian epithelial cancer</keyword>
  <keyword>stage IIC ovarian epithelial cancer</keyword>
  <keyword>stage IIIA ovarian epithelial cancer</keyword>
  <keyword>stage IIIB ovarian epithelial cancer</keyword>
  <keyword>stage IIIC ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adjuvants, Immunologic</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

